On behalf of my radiation oncology partner, Dr. Arjun Sahgal, I am pleased to offer to the readers of Frontiers in Oncology our Research Topic entitled, “Contemporary management of intracranial metastatic disease.” The development of intracranial metastatic disease (IMD) complicates the course of ~20% of patients with cancer, with the highest frequency of brain metastases arising in patients with melanoma, breast cancer, and lung cancer (, ). Modern therapeutic options available for treatment of IMD include surgical resection, stereotactic radiosurgery (SRS) and to an expanding degree, targeted, and immuno-therapies (). Despite improvements in patient survival with more aggressive treatment options as compared to the prior standard of palliative whole brain radiation, outcomes for patients who develop IMD remain dispiriting. There is need to celebrate our advances; but a major collaborative multidisciplinary effort is needed to push the field to achieve more meaningful survival benefits for our patients with IMD.
In this Research Topic, we have assembled work detailing the latest innovations in brain metastases imaging and management. Mehrabian et al. have reviewed work in the MR imaging field to identify advanced biomarkers that characterize the cellular, biophysical, micro-structural, and metabolic features of tumors to improve the management of brain metastases from early detection and diagnosis, to evaluating treatment response. Venur et al. review the contribution of genomic analysis of brain metastases to our understanding of variations in the driver mutations compared to the primary malignancy, and provide an in-depth review of the completed and ongoing clinical trials of drugs targeting the molecular pathways enriched in brain metastases. Kamath and Kumthekar review the biological rationale for systemic immunotherapy to treat CNS metastatic disease, and summarize existing clinical data on immune checkpoint inhibitors in this setting and ongoing clinical trials designed to study immune checkpoint inhibitor therapy in patients with IMD. Meng et al. review the prospect of focused ultrasound-mediated blood-brain barrier disruption to improve local drug delivery for patients with IMD. Minimally invasive surgical strategies using tubular retractors or laser interstitial thermal therapy (LITT) have been presented by Marenco-Hillembrand et al. and Salehi et al., respectively. Routman et al. review data to support the use of SRS as a neoadjuvant therapy to improve treatment contouring and diminish the risk of tumor cell dissemination during surgical resection and associated leptomeningeal spread. Masucci and Routman et al. detail the role of hyprofractionated SRS and post-operative SRS, respectively, for patients with IMD. Robin and Rusthoven and Schwendner et al. have reviewed efforts to minimize disease- and treatment-related cognitive and motor decline in patients with IMD. Vellayappan et al. explore the pathophysiology of radiation necrosis, risk factors for its development, and the strategies for its evaluation and management. Finally, Samuel Chao and colleagues define a treatment algorithm to guide treatment of patients with a limited number of brain metastases, while Roberge et al. describe plans for a prospective randomized control trial to define the role of SRS in patients with more severe burden of IMD.
In all of this, we owe thanks to our many colleagues who contributed to this Research Topic and offered us their time, intellect and energy. Many thanks as well to Jakob Mainusch and the editorial team at Frontiers. We thank Frontiers for appreciating the importance of this topic and for supporting the collection. We hope that you find it a valuable resource.
Statements
Author contributions
SD wrote and edited the manuscript. AS edited the manuscript and provided guidance on its writing.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1.
AchrolASRennertRCAndersCSoffiettiRAhluwaliaMSNayakLet al. Brain metastases. Nat Rev Dis Primers. (2019) 5:5. 10.1038/s41572-018-0055-y
2.
CagneyDNMartinAMCatalanoPJRedigAJLinNULeeEQet al. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. (2017) 19:1511–21. 10.1093/neuonc/nox077
3.
KotechaRGondiVAhluwaliaMSBrastianosPKMehtaMP. Recent advances in managing brain metastasis [version 1; peer review: 2 approved]. F1000Res. (2018) 7:1772. 10.12688/f1000research.15903.1
Summary
Keywords
brain metastases (BM), surgery, immunotherapy, focused ultrasound, chemotherapy, targeted therapy, radiotherapy, SRS
Citation
Das S and Sahgal A (2019) Editorial: Contemporary Management of Intracranial Metastatic Disease. Front. Oncol. 9:818. doi: 10.3389/fonc.2019.00818
Received
18 June 2019
Accepted
09 August 2019
Published
28 August 2019
Volume
9 - 2019
Edited and reviewed by
Erik P. Sulman, New York University, United States
Updates
Copyright
© 2019 Das and Sahgal.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Sunit Das sunit.das@utoronto.ca
This article was submitted to Neuro-Oncology and Neurosurgical Oncology, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.